[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2010030201A3 - Stable oral pharmaceutical composition containing a pharmaceutically acceptable salt of [(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidine-5-yl] (3r, 5s) - 3,5 dihydroxyhept-6- enoic acid - Google Patents

Stable oral pharmaceutical composition containing a pharmaceutically acceptable salt of [(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidine-5-yl] (3r, 5s) - 3,5 dihydroxyhept-6- enoic acid Download PDF

Info

Publication number
WO2010030201A3
WO2010030201A3 PCT/PL2009/000084 PL2009000084W WO2010030201A3 WO 2010030201 A3 WO2010030201 A3 WO 2010030201A3 PL 2009000084 W PL2009000084 W PL 2009000084W WO 2010030201 A3 WO2010030201 A3 WO 2010030201A3
Authority
WO
WIPO (PCT)
Prior art keywords
dihydroxyhept
methylsulfonyl
fluorophenyl
pyrimidine
isopropyl
Prior art date
Application number
PCT/PL2009/000084
Other languages
French (fr)
Other versions
WO2010030201A2 (en
Inventor
Anna Madanecka
Aleksandra Tukalska
Magdalena Grabowska
Original Assignee
Zaklady Farmaceutyczne Polpharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zaklady Farmaceutyczne Polpharma Sa filed Critical Zaklady Farmaceutyczne Polpharma Sa
Publication of WO2010030201A2 publication Critical patent/WO2010030201A2/en
Publication of WO2010030201A3 publication Critical patent/WO2010030201A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The stable oral pharmaceutical composition containing as the active ingredient [(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidine-5-yl] (3R, 5S) - 3,5 dihydroxyhept-6-enoic acid or its pharmaceutically acceptable salt, one or more fillers, one or more disintegrants, one or more lubricants, coating agents, and one or more stabilizers.
PCT/PL2009/000084 2008-09-09 2009-09-02 Stable oral pharmaceutical composition containing a pharmaceutically acceptable salt of [(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidine-5-yl] (3r, 5s) - 3,5 dihydroxyhept-6- enoic acid WO2010030201A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PLP-386051 2008-09-09
PL386051A PL386051A1 (en) 2008-09-09 2008-09-09 Stable, oral compound pharmaceutical containing pharmaceutically permissible content of [(E)-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidine-5-yl] (3R,5S)-3,5-dihydroxy-hept-6-enoate acid salt

Publications (2)

Publication Number Publication Date
WO2010030201A2 WO2010030201A2 (en) 2010-03-18
WO2010030201A3 true WO2010030201A3 (en) 2010-07-22

Family

ID=42005665

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/PL2009/000084 WO2010030201A2 (en) 2008-09-09 2009-09-02 Stable oral pharmaceutical composition containing a pharmaceutically acceptable salt of [(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidine-5-yl] (3r, 5s) - 3,5 dihydroxyhept-6- enoic acid

Country Status (2)

Country Link
PL (1) PL386051A1 (en)
WO (1) WO2010030201A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200904341A2 (en) * 2009-06-03 2010-12-21 Bi̇lgi̇ç Mahmut Stable pharmaceutical compositions containing rosuvastatin calcium.
TR201009399A2 (en) * 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Rapidly soluble effervescent rosuvastatin formulations.
US20140179712A1 (en) 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide
BR112017009521A2 (en) 2014-11-11 2017-12-19 Shionogi & Co multilayer tablet containing a light-unstable drug

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5180589A (en) * 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
WO2001054669A1 (en) * 2000-01-26 2001-08-02 Astrazeneca Ab Pharmaceutical compositions comprising a hmg coa reductase inhibitor
WO2007071357A2 (en) * 2005-12-20 2007-06-28 Lek Pharmaceuticals D.D. Pharmaceutical composition comprising (e) -7- [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin-5 -yl- (3r, 5s) -3, 5-dihydr0xyhept-6-en0ic acid
WO2008035128A1 (en) * 2006-09-18 2008-03-27 Richter Gedeon Nyrt. Pharmaceutical compositions containing rosuvastatin calcium
WO2009112870A1 (en) * 2008-03-11 2009-09-17 Belupo-Lijekovi I Kozmetika D.D. Pharmaceutical composition comprising rosuvastatin calcium and magnesium carbonate hydroxide pentahydrate as a stabilizer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5180589A (en) * 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
WO2001054669A1 (en) * 2000-01-26 2001-08-02 Astrazeneca Ab Pharmaceutical compositions comprising a hmg coa reductase inhibitor
WO2007071357A2 (en) * 2005-12-20 2007-06-28 Lek Pharmaceuticals D.D. Pharmaceutical composition comprising (e) -7- [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin-5 -yl- (3r, 5s) -3, 5-dihydr0xyhept-6-en0ic acid
WO2008035128A1 (en) * 2006-09-18 2008-03-27 Richter Gedeon Nyrt. Pharmaceutical compositions containing rosuvastatin calcium
WO2009112870A1 (en) * 2008-03-11 2009-09-17 Belupo-Lijekovi I Kozmetika D.D. Pharmaceutical composition comprising rosuvastatin calcium and magnesium carbonate hydroxide pentahydrate as a stabilizer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Core Data Sheet Crestor(TM) Tablets", INTERNET CITATION, 5 September 2007 (2007-09-05), XP002449400, Retrieved from the Internet <URL:http://www.crestor.info/gUserFiles/CRESTOR_CDS_10_40_FINAL_170603.pdf> [retrieved on 20070905] *

Also Published As

Publication number Publication date
PL386051A1 (en) 2010-03-15
WO2010030201A2 (en) 2010-03-18

Similar Documents

Publication Publication Date Title
AP1449A (en) Pharmaceutical compositions comprising a hmg reductase inhibitor.
HUS1600061I1 (en) Salt of 4[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile
IL155919A (en) (e) - 7 - [4 - (4 - fluorophenyl) - 6 - isopropyl - 2 - [methyl ( methylsulfonyl) amino] pyrimidin - 5 - yl] (3r, 5s) - dihydroxyhept - 6 - enoic acid, or a pharmaceutically acceptable salt thereof, for use as a medicament for the treatment of heterozygous familial hypercholesterolemia
HK1055958A1 (en) Crystalline salts of 7-Ä4-(4-fluorophenyl)-6-isopropyl-2-Ämethyl(methylsul-fonyl)aminoÜpyrimidin-5-ylÜ-(3R,5S)-3,5-dihydroxyhept-6-enoic acid
WO2007071357A3 (en) Pharmaceutical composition comprising (e) -7- [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin-5 -yl- (3r, 5s) -3, 5-dihydr0xyhept-6-en0ic acid
WO2010030201A3 (en) Stable oral pharmaceutical composition containing a pharmaceutically acceptable salt of [(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidine-5-yl] (3r, 5s) - 3,5 dihydroxyhept-6- enoic acid
HK1112862A1 (en)
WO2009091346A3 (en) Stable pharmaceutical formulation and preparation methods
UA92469C2 (en) Fumarate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl amino benzonitrile
UY30336A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING ACID (E) -7- (4- (4-FLUOROPHENYL) -6-ISOPROPIL-2- (METHYL (METILSULFONIL) AMINO) PIRIMIDIN-5-IL) - (3R, 5S) -3,5-DIHYDROXIHEPT -6-ENOICO AND PHARMACEUTICALLY ACCEPTABLE SALTS OF THE SAME
MX2008001705A (en) Comination of a hypnotic agent and r(+)-alpha-(2,3-dimethoxy-phen yl)-1-[2-(4-fluorophenl)ethyl]-4-piperidinemethanol and therapeutic application thereof.
HRP20110563T1 (en) Salt of 4[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
UY27049A1 (en) PHARMACEUTICAL COMPOSITIONS

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09737189

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 09737189

Country of ref document: EP

Kind code of ref document: A2